Xeriant Reports Improved Net Loss of $1.32 Million for Nine Months Ending March 31, 2025

Xeriant, Inc. has reported its financial results for the nine months ending March 31, 2025, revealing a net loss of $1.32 million, a decrease from a loss of $1.93 million during the same period in the previous year. The company’s total operating expenses increased to $1.15 million from $1.01 million year-over-year, primarily driven by higher consulting and advisory fees, which rose to $266,720 from $193,995. The increase in expenses is attributed to new and restructured agreements with advisory board members. Despite the rise in operating expenses, the overall net loss improved due to a significant reduction in other expenses, which fell to $166,463 from $921,206, largely due to the absence of default interest related to a previous loan.

In terms of operational metrics, Xeriant's cash reserves decreased significantly, ending the reporting period with $53,587 compared to $653,117 at the end of June 2024. The company also reported a working capital deficit of $8.6 million, raising concerns about its ability to continue as a going concern. As of March 31, 2025, Xeriant had 681,131,059 shares of common stock outstanding, an increase from 524,853,304 shares a year earlier, reflecting ongoing efforts to raise capital through equity issuance.

Strategically, Xeriant has focused on developing its advanced materials line, particularly the DUREVER™ brand, which includes the eco-friendly NEXBOARD™ composite construction panel. The company has appointed two senior advisors with expertise in nanomaterials to enhance its product portfolio. Xeriant is also exploring manufacturing opportunities for NEXBOARD™ and has engaged in discussions with potential contract manufacturers to meet market demand. However, the company has not yet established production capabilities and will require significant capital to do so.

Xeriant's recent activities also include legal proceedings against Auctus Fund LLC and XTI Aircraft Company, which may impact its financial position. The company is seeking to enforce terms of a letter agreement and recover damages exceeding $500 million from XTI, alleging fraudulent acts and breaches of contract. The outcome of these legal matters could have significant implications for Xeriant's future operations and financial health.

Looking ahead, Xeriant's management has indicated that the company will need to raise additional capital to fund its operations and continue its strategic initiatives. The ability to secure financing remains uncertain, and the company has acknowledged that failure to raise adequate capital could result in curtailing or ceasing operations. As Xeriant navigates these challenges, its focus will remain on developing its advanced materials and aerospace technologies while addressing its financial and operational hurdles.